InsidersTradesSigma
Track the Tandem Diabetes Care, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was reported on 18 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: MARK NOVARA. The full history is openly available.
Analysts rate Tandem Diabetes Care, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$61.47.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Tandem Diabetes Care, Inc. is a company focused on developing medical devices for diabetes management. It concentrates on innovative solutions to enhance the quality of life for individuals with diabetes.